TCRX FY 2021 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+834.7% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$49M-479.6% margin

Net Income

-$49M-479.5% margin

EPS (Diluted)

$-2.03

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$59M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$188M

Total Liabilities

$27M

Stockholders' Equity

$161M

Cash & Equivalents

$161M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$1M	+834.7%
Gross Profit	$10M	-$19M	+152.0%
Operating Income	-$49M	-$26M	-85.4%
Net Income	-$49M	-$26M	-86.1%